Sana Biotechnology

Founded 2018 · CIK 0001770121 · Biotech

sana.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$867M
2 Form D · Jun 2020
76 months since last filing
Contracts
—
No federal contracts on record
Patents
40
3 granted · 37 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raised· 1 of 2 same dayForm D · SEC$821,097,521
Private capital raised· 2 of 2 same dayForm D · SEC$45,850,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1119DURAVAX INC——
1120XGENOMES CORP.——
1121LYTICON, LLC——
1122Sana Biotechnology—$867M
1123Walden Biosciences——
1124Kriya Therapeutics—$769M
1125VERSATOPE THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • Hans BishopDirector
  • Douglas ColeDirector
  • Nathan HardyExecutive Officer
  • Steven HarrDirector · Executive Officer
  • Stephen KnightDirector
  • James MacDonaldExecutive Officer
  • Richard MulliganDirector
  • Robert NelsenDirector
  • Donald PayanDirector
  • Geoffrey von MaltzahnDirector
  • Mary Agnes WilderotterDirector
  • Patrick YangDirector

Patents

USPTO · 3 granted of 40
  • Engineering Cells With A Transgene In B2M Or Ciita Locus And Associated Compositions And Methodsapplication
  • CD8-SPECIFIC Antibody Constructs And Compositions Thereofapplication
  • Viral Particles With Fusogen Display And Related Compositions And Methodsapplication
  • Methods And Compositions For Modulating Car-t Activitygranted
  • CD8-SPECIFIC Antibody Constructs And Compositions Thereofgranted
  • Hypoimmunogenic Mait Cells, Methods Of Making And Methods Of Using Sameapplication
  • Methods Of Delivery Of Islet Cells And Related Methodsapplication
  • Lipid Particles Comprising Variant Paramyxovirus Attachment Glycoproteins And Uses Thereofapplication
  • Delivery Of Heterologous Proteinsapplication
  • Inducible Systems For Altering Gene Expression In Hypoimmunogenic Cellsapplication
  • Methods Of Dosing And Administration Of Engineered Islet Cellsapplication
  • Methods Of Transduction Using A Viral Vector And Inhibitors Of Antiviral Restriction Factorsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.